Concepts (163)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 15 | 2019 | 1679 | 1.910 |
Why?
|
| Receptor, erbB-2 | 5 | 2019 | 149 | 1.540 |
Why?
|
| Epigenesis, Genetic | 3 | 2019 | 274 | 0.940 |
Why?
|
| Drug Resistance, Neoplasm | 6 | 2019 | 290 | 0.930 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2019 | 933 | 0.920 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2014 | 297 | 0.680 |
Why?
|
| S100 Proteins | 1 | 2019 | 13 | 0.610 |
Why?
|
| Neoplasm Proteins | 2 | 2013 | 228 | 0.580 |
Why?
|
| Cell Line, Tumor | 11 | 2019 | 2598 | 0.550 |
Why?
|
| Chromatin | 1 | 2019 | 179 | 0.540 |
Why?
|
| Transforming Growth Factor beta | 1 | 2017 | 214 | 0.470 |
Why?
|
| Signal Transduction | 5 | 2019 | 2111 | 0.460 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 683 | 0.460 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2014 | 29 | 0.430 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2013 | 59 | 0.410 |
Why?
|
| Organic Cation Transport Proteins | 1 | 2012 | 13 | 0.390 |
Why?
|
| Prostatic Neoplasms | 3 | 2022 | 1068 | 0.390 |
Why?
|
| Neoplasms | 2 | 2022 | 1341 | 0.360 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2014 | 81 | 0.350 |
Why?
|
| Forkhead Transcription Factors | 2 | 2014 | 75 | 0.350 |
Why?
|
| Transcription Factors | 3 | 2015 | 722 | 0.330 |
Why?
|
| Caspase 8 | 1 | 2010 | 32 | 0.320 |
Why?
|
| Serpins | 1 | 2010 | 29 | 0.320 |
Why?
|
| CpG Islands | 1 | 2010 | 107 | 0.320 |
Why?
|
| Antibodies, Monoclonal | 1 | 2010 | 301 | 0.290 |
Why?
|
| Humans | 22 | 2022 | 42163 | 0.280 |
Why?
|
| Amino Acid Transport Systems | 1 | 2006 | 5 | 0.260 |
Why?
|
| Pyrazoles | 2 | 2017 | 93 | 0.260 |
Why?
|
| Paclitaxel | 1 | 2006 | 64 | 0.250 |
Why?
|
| DNA Methylation | 1 | 2010 | 393 | 0.250 |
Why?
|
| Antineoplastic Agents | 4 | 2022 | 979 | 0.240 |
Why?
|
| Amino Acids | 1 | 2006 | 150 | 0.240 |
Why?
|
| Cell Proliferation | 5 | 2017 | 1420 | 0.240 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2006 | 134 | 0.230 |
Why?
|
| Chromatin Immunoprecipitation | 2 | 2019 | 74 | 0.230 |
Why?
|
| beta Catenin | 2 | 2017 | 75 | 0.220 |
Why?
|
| Estrogen Receptor alpha | 2 | 2015 | 120 | 0.210 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2017 | 28 | 0.200 |
Why?
|
| Female | 14 | 2018 | 24018 | 0.200 |
Why?
|
| Apoptosis | 3 | 2022 | 1541 | 0.200 |
Why?
|
| Receptors, Calcitriol | 2 | 2014 | 69 | 0.200 |
Why?
|
| Endothelial Growth Factors | 1 | 2002 | 9 | 0.190 |
Why?
|
| Lymphokines | 1 | 2002 | 17 | 0.190 |
Why?
|
| Enzyme Inhibitors | 3 | 2010 | 457 | 0.180 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2017 | 180 | 0.170 |
Why?
|
| Exosomes | 1 | 2022 | 124 | 0.160 |
Why?
|
| Epidermal Growth Factor | 1 | 2019 | 69 | 0.150 |
Why?
|
| Morpholines | 2 | 2010 | 73 | 0.140 |
Why?
|
| Cell Movement | 3 | 2017 | 640 | 0.140 |
Why?
|
| Chromones | 2 | 2010 | 53 | 0.140 |
Why?
|
| Phenylthiohydantoin | 1 | 2017 | 3 | 0.140 |
Why?
|
| Hela Cells | 1 | 2019 | 370 | 0.140 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2017 | 25 | 0.140 |
Why?
|
| Androgen Antagonists | 1 | 2017 | 29 | 0.140 |
Why?
|
| Triazines | 1 | 2017 | 25 | 0.140 |
Why?
|
| Histones | 1 | 2019 | 194 | 0.140 |
Why?
|
| Pyrroles | 1 | 2017 | 68 | 0.130 |
Why?
|
| Thiosemicarbazones | 1 | 2017 | 10 | 0.130 |
Why?
|
| Chemokine CXCL1 | 1 | 2017 | 18 | 0.130 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2017 | 25 | 0.130 |
Why?
|
| Chemokine CCL2 | 1 | 2018 | 95 | 0.130 |
Why?
|
| Polymorphism, Restriction Fragment Length | 2 | 2014 | 29 | 0.130 |
Why?
|
| Pyrimidines | 1 | 2017 | 130 | 0.130 |
Why?
|
| Models, Biological | 3 | 2022 | 711 | 0.130 |
Why?
|
| RNA, Messenger | 3 | 2013 | 1265 | 0.120 |
Why?
|
| Haplotypes | 2 | 2014 | 197 | 0.120 |
Why?
|
| Cadherins | 2 | 2014 | 102 | 0.120 |
Why?
|
| Gene Expression | 1 | 2018 | 692 | 0.110 |
Why?
|
| Cysteine-Rich Protein 61 | 1 | 2014 | 3 | 0.110 |
Why?
|
| 9,10-Dimethyl-1,2-benzanthracene | 1 | 2014 | 28 | 0.110 |
Why?
|
| Mammary Glands, Animal | 1 | 2014 | 23 | 0.110 |
Why?
|
| Lactation | 1 | 2014 | 44 | 0.110 |
Why?
|
| Animals | 6 | 2022 | 16695 | 0.100 |
Why?
|
| Drug Synergism | 2 | 2013 | 189 | 0.100 |
Why?
|
| STAT3 Transcription Factor | 1 | 2013 | 97 | 0.100 |
Why?
|
| Neoplastic Stem Cells | 1 | 2013 | 94 | 0.100 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2013 | 649 | 0.090 |
Why?
|
| Los Angeles | 1 | 2013 | 390 | 0.090 |
Why?
|
| Middle Aged | 5 | 2014 | 11819 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2018 | 136 | 0.090 |
Why?
|
| Disease-Free Survival | 2 | 2013 | 116 | 0.090 |
Why?
|
| Transcriptional Activation | 1 | 2012 | 173 | 0.090 |
Why?
|
| Mice, Transgenic | 1 | 2014 | 658 | 0.090 |
Why?
|
| Alleles | 1 | 2013 | 352 | 0.090 |
Why?
|
| Mice | 4 | 2015 | 6490 | 0.090 |
Why?
|
| Nuclear Proteins | 1 | 2012 | 330 | 0.080 |
Why?
|
| Male | 5 | 2022 | 22779 | 0.080 |
Why?
|
| Hydroxamic Acids | 1 | 2010 | 34 | 0.080 |
Why?
|
| Phenotype | 1 | 2012 | 774 | 0.080 |
Why?
|
| Enzyme Activation | 1 | 2010 | 462 | 0.080 |
Why?
|
| Transfection | 1 | 2010 | 526 | 0.080 |
Why?
|
| Disease Models, Animal | 1 | 2014 | 1554 | 0.070 |
Why?
|
| Down-Regulation | 1 | 2010 | 452 | 0.070 |
Why?
|
| Colorectal Neoplasms | 1 | 2014 | 502 | 0.070 |
Why?
|
| Promoter Regions, Genetic | 1 | 2010 | 534 | 0.070 |
Why?
|
| Ethylmaleimide | 1 | 2006 | 8 | 0.070 |
Why?
|
| Starvation | 1 | 2006 | 12 | 0.070 |
Why?
|
| Maleimides | 1 | 2006 | 12 | 0.070 |
Why?
|
| Alanine | 1 | 2006 | 33 | 0.070 |
Why?
|
| Survival Analysis | 1 | 2008 | 362 | 0.060 |
Why?
|
| Multivariate Analysis | 2 | 2014 | 638 | 0.060 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2006 | 138 | 0.060 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2006 | 5 | 0.060 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2006 | 52 | 0.060 |
Why?
|
| Sodium | 1 | 2006 | 101 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 2 | 2018 | 284 | 0.060 |
Why?
|
| Caspases | 1 | 2006 | 148 | 0.060 |
Why?
|
| Blotting, Northern | 1 | 2006 | 149 | 0.060 |
Why?
|
| Doxorubicin | 1 | 2006 | 95 | 0.060 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2006 | 271 | 0.060 |
Why?
|
| Imidazoles | 1 | 2006 | 138 | 0.060 |
Why?
|
| Flavonoids | 1 | 2006 | 94 | 0.060 |
Why?
|
| Immunohistochemistry | 1 | 2008 | 928 | 0.060 |
Why?
|
| Pyridines | 1 | 2006 | 134 | 0.060 |
Why?
|
| Adult | 3 | 2013 | 13458 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 2 | 2017 | 506 | 0.050 |
Why?
|
| Base Sequence | 1 | 2006 | 997 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2017 | 209 | 0.050 |
Why?
|
| RNA, Small Interfering | 2 | 2018 | 436 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2006 | 1112 | 0.050 |
Why?
|
| Amino Acid Sequence | 1 | 2006 | 1188 | 0.050 |
Why?
|
| Molecular Sequence Data | 1 | 2006 | 1559 | 0.050 |
Why?
|
| Transcription, Genetic | 1 | 2006 | 599 | 0.050 |
Why?
|
| Phosphorylation | 2 | 2018 | 973 | 0.050 |
Why?
|
| Hormones | 1 | 2022 | 56 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2002 | 10 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2002 | 53 | 0.050 |
Why?
|
| Menopause | 1 | 2002 | 63 | 0.050 |
Why?
|
| Recurrence | 1 | 2002 | 149 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 1 | 2022 | 137 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2006 | 1066 | 0.040 |
Why?
|
| Ligands | 1 | 2022 | 387 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2014 | 1266 | 0.040 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2018 | 95 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2002 | 1586 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2018 | 188 | 0.030 |
Why?
|
| Nitriles | 1 | 2017 | 78 | 0.030 |
Why?
|
| Time Factors | 1 | 2002 | 1848 | 0.030 |
Why?
|
| Benzamides | 1 | 2017 | 78 | 0.030 |
Why?
|
| Androgens | 1 | 2017 | 107 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 233 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 456 | 0.030 |
Why?
|
| MicroRNAs | 1 | 2022 | 501 | 0.030 |
Why?
|
| 3T3 Cells | 1 | 2014 | 61 | 0.030 |
Why?
|
| Tamoxifen | 1 | 2015 | 67 | 0.030 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2015 | 69 | 0.030 |
Why?
|
| Cell Survival | 1 | 2017 | 934 | 0.030 |
Why?
|
| Cyclic S-Oxides | 1 | 2013 | 2 | 0.030 |
Why?
|
| NIH 3T3 Cells | 1 | 2013 | 64 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2013 | 79 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2015 | 403 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2013 | 128 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2014 | 189 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2014 | 454 | 0.020 |
Why?
|
| Disease Progression | 1 | 2015 | 661 | 0.020 |
Why?
|
| Survival Rate | 1 | 2013 | 353 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2013 | 884 | 0.020 |
Why?
|
| Genotype | 1 | 2014 | 796 | 0.020 |
Why?
|
| Vitamin D | 1 | 2013 | 196 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2014 | 1729 | 0.020 |
Why?
|
| Aged | 1 | 2002 | 7982 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2014 | 860 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2014 | 2485 | 0.020 |
Why?
|